Menlo Advisors buys $2,045,702 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Menlo Advisors scooped up 100 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 12, 2016. The investment management firm now holds a total of 48,742 shares of Abbott Laboratories which is valued at $2,045,702.Abbott Laboratories makes up approximately 1.71% of Menlo Advisors’s portfolio.

Other Hedge Funds, Including , Palisade Asset Management boosted its stake in ABT in the latest quarter, The investment management firm added 11,891 additional shares and now holds a total of 245,866 shares of Abbott Laboratories which is valued at $10,318,996. Abbott Laboratories makes up approx 1.92% of Palisade Asset Management’s portfolio.Dnb Asset Management As reduced its stake in ABT by selling 111,100 shares or 23.59% in the most recent quarter. The Hedge Fund company now holds 359,876 shares of ABT which is valued at $15,075,206. Abbott Laboratories makes up approx 0.31% of Dnb Asset Management As’s portfolio.Trust Co boosted its stake in ABT in the latest quarter, The investment management firm added 1,737 additional shares and now holds a total of 91,797 shares of Abbott Laboratories which is valued at $3,845,376. Abbott Laboratories makes up approx 1.45% of Trust Co’s portfolio.Kistler-tiffany Companies reduced its stake in ABT by selling 1,174 shares or 16.06% in the most recent quarter. The Hedge Fund company now holds 6,136 shares of ABT which is valued at $257,037. Abbott Laboratories makes up approx 0.13% of Kistler-tiffany Companies’s portfolio.

Abbott Laboratories closed down -0.18 points or -0.43% at $42.1 with 76,93,538 shares getting traded on Friday. Post opening the session at $42.4, the shares hit an intraday low of $42.025 and an intraday high of $42.53 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.